The predictive value of preoperative serum neutrophil-to-lymphocyte ratio and tumor markers for early breast cancer patients: A retrospective study

Article Oncology

The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+subtype

Satu Tiainen et al.

Summary: High NLR and MLR were associated with poor overall survival and breast cancer specific survival among all patients. In HER2+ patients who did not receive trastuzumab, high NLR or MLR was correlated with lower survival rates.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Medical Laboratory Technology

The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer

Jingya Zhang et al.

Summary: This study investigated the application value of tumor markers in monitoring distant metastasis of breast cancer, revealing that combined detection of multiple markers is more valuable than using a single tumor marker.

CLINICA CHIMICA ACTA (2021)

Add to Collection

Review Oncology

Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?

Jiajie Hou et al.

Summary: The immune system plays crucial roles in cancer development and treatment, with adaptive immunity capable of preventing or constraining cancer and innate immunity and inflammation often promoting tumorigenesis. While immunotherapies derived from preclinical studies have shown efficacy in treating cancer, treatments targeting cancer-associated inflammation still require successful implementation. Anti-inflammatory agents have the potential to delay cancer onset and enhance the efficacy of conventional and next-generation cancer therapies.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients

Jiujun Zhu et al.

Summary: Neutrophils and lymphocytes play crucial roles in breast cancer development and progression. The Neutrophil to lymphocyte ratio (NLR) has been shown to be a valuable prognostic marker for evaluating BC patients. Lower baseline NLR values are associated with a higher likelihood of achieving pathological complete response (pCR) following neoadjuvant chemotherapy (NCT) treatment.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Effects of systemic inflammation on relapse in early breast cancer

Nicholas P. McAndrew et al.

Summary: Chronic inflammation has been proposed as a mechanism of resistance to aromatase inhibitors in breast cancer. A study found that elevated serum inflammatory biomarkers CRP and SAA were significantly associated with an increased risk of recurrence in hormone receptor positive breast cancer, while high-risk IL-6 promoter polymorphisms were strongly associated with HER2+ breast cancer relapse.

NPJ BREAST CANCER (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group

Ceren Boyaci et al.

Summary: The study demonstrates high reproducibility and independent prognostic potential in using IKWG guidelines to score Ki67 in breast cancer. Machine-read scores showed similar and significant hazard ratios for relapse-free survival in an ER+ breast cancer cohort.

BIOMOLECULES (2021)

Add to Collection

Article Multidisciplinary Sciences

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer

Shogo Nakamoto et al.

Summary: This study revealed that high ALC, low NLR, and high LMR are associated with longer TTF and OS in patients with HER2-negative ABC who underwent PB therapy. These systemic immunity markers may serve as predictive markers for the effectiveness of PB therapy in these patients.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Systemic inflammation markers and cancer incidence in the UK Biobank

Therese Haugdahl Nost et al.

Summary: Systemic inflammation markers are associated with increased cancer risk and mortality. This study found associations between pre-diagnostic systemic inflammation markers and cancer risk, with SII showing the strongest impact on colorectal and lung cancer risk.

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2021)

Add to Collection

Article Genetics & Heredity

Breast cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes and risk management behavior

Tatiane Yanes et al.

Summary: The study found that the majority of women chose to receive their breast cancer polygenic risk score, with high-risk individuals reporting more distress and decisional regret. After 12 months, breast screening and risk-reducing strategies were consistent with guidelines, highlighting the importance of addressing emotional responses in genetic counseling models.

GENETICS IN MEDICINE (2021)

Add to Collection

Article Geriatrics & Gerontology

Association of systemic inflammation with survival in patients with cancer cachexia: results from a multicentre cohort study

Qi Zhang et al.

Summary: This study found that the neutrophil-to-lymphocyte ratio (NLR) is associated with the survival and quality of life of cancer cachexia patients, with an increase in NLR showing an inverted L-shaped dose-response association with all-cause mortality. An NLR of 3.5 or greater could independently predict overall survival in cancer patients, and this association was consistent across cancer subtypes.

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2021)

Add to Collection

Article Oncology

Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis

Xiaomin Li et al.

Summary: The NLR and LNR are predictive of prognosis in patients with breast cancer undergoing neoadjuvant chemotherapy, with low NLR and LNR suggesting favorable outcomes.

CANCER MANAGEMENT AND RESEARCH (2021)

Add to Collection

Article Oncology

Time-Sequencing of the Neutrophil-to-Lymphocyte Ratio to Predict Prognosis of Triple-Negative Breast Cancer

Joo-Heung Kim et al.

Summary: While the prognosis of triple-negative breast cancer (TNBC) varies, identifying subgroups with particularly poor prognosis is crucial. This study aimed to investigate the association between changes in the neutrophil-to-lymphocyte ratio (NLR) during treatment and poor prognosis in TNBC patients. The findings suggest that an increase in NLR during treatment may indicate a higher risk of recurrence or death, highlighting the need for additional treatment modalities.

CANCERS (2021)

Add to Collection

Article Cell Biology

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting

Antonino Grassadonia et al.

Summary: The study found that in patients with luminal breast cancer receiving neoadjuvant chemotherapy, pre-treatment NLRlow was significantly associated with shorter DFS and OS. Additionally, non-ductal histology, luminal B subtype, and post-treatment Ki67 >= 14% were also associated with worse DFS.

CELLS (2021)

Add to Collection

Review Oncology

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer

Samitha Andrahennadi et al.

Summary: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is commonly treated with endocrine therapy such as tamoxifen and aromatase inhibitors, showing significant reduction in mortality for early-stage patients. The use of CDK 4/6 inhibitors, mTOR inhibitors, and PI3K inhibitors in combination with endocrine therapy has demonstrated improved outcomes and delayed initiation of chemotherapy in advanced HR + BC. Numerous novel agents are currently being studied for the treatment of HR + BC, indicating a promising future for overcoming resistance and improving outcomes.

CURRENT ONCOLOGY (2021)

Add to Collection

Article Oncology